IL-18 stimulates B-type natriuretic peptide synthesis by cardiomyocytes in vitro and its plasma levels correlate with B-type natriuretic peptide in non-overloaded acute heart failure patients

European Heart Journal: Acute Cardiovascular Care

Volumn 6, Issue 5, 2017, Pages 450-461

  Di Somma, Salvatore ^a   Pittoni, Valerio ^a   Raffa, Salvatore ^a   Magrini, Laura ^a   Gagliano, Giulia ^a   Marino, Rossella ^a   Nobili, Valerio ^a   Torrisi, Maria Rosaria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Heart failure; hormones; inflammation; interleukins

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DESMIN; INTERLEUKIN 18; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B;

ACUTE HEART FAILURE; ADULT; AGED; ANIMAL CELL; ARTICLE; CARDIAC MUSCLE CELL; CELL MEMBRANE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; MALE; MIDDLE AGED; MURINE; NONHUMAN; PEPTIDE SYNTHESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 85060068634     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872613499282     Document Type: Article

References (46)

1. Yndestad A, Kristian Damas JK. Systemic inflammation in heart failure-the whys and wherefores. Heart Fail Rev 2006; 11: 83–92.
2. Calabrese F, van der Wal AC, Levi M. Infection and inflammation in the cardiovascular system. Cardiovasc Res 2003; 60: 1–4.
3. Aukrust P, Gullestad L, Ueland T. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutical implications. Ann Med 2005; 37: 74–85.
4. Yndestat A, Holm AM, Müller F. Enhanced expression of inflammatory cytokines and activation markers in T-cell from patients with chronic heart failure. Cardiovasc Res 2003; 60: 141–146.
5. Gwechenberger M, Hülsmann M, Berger R. Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive heart failure. J Heart Lung Transplant 2004; 23: 839–844.
6. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M. Prognostic value or interleukin-8 as a predictor of heart failure in patients with myocardial infarction and percutaneous intervention. Int J Cardiol 2006; 111: 158–160.
7. Ueland T, Kjekshus J, Froland SS. Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. J Am Coll Cardiol 2005; 46: 2018–2021.
8. Rauchhaus M, Doehner W, Francis DP. Plasma cytokine parameters and mortality in patients with congestive heart failure. Circulation 2000; 102: 3060–3067.
9. Okamura H, Tsutsui H, Komatsu T. Cloning of a new cytokine that induces interferon-γ. Nature 1995; 378: 88–91.
10. Dinarello CA. Interleukin-18, a proinflammatory cytokine. Eur Cytokine Netw 2000; 11: 483–486.
11. Mallat Z, Heymes C, Corbaz A. Evidence of altered interleukin-18 (IL-18) pathway in human heart failure. FASEB J 2004; 18: 1752–1754.
12. Woldbaek PR, Sande BJ, Stromme TA. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart Circ Physiol 2005; 89: 708–714.
13. Daniel LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357–2368.
14. Di Angelantonio E, Chowdhury R, Sarwar N. B-type natriuretic peptides and cardiovascular risk. Systematic review and meta-analysis of 40 prospective studies. Circulation 2009; 120: 2177–2187.
15. Di Somma S, Magrini L, Pittoni V. Usefulness of serial assessment of natriuretic peptides in the emergency department for patients with acute decompensated heart failure. Congest Heart Fail 2008; 14: 21–24.
16. Maisel A, Mueller C, Adams K, Jr. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824–839.
17. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and traslational levels by proinflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 2004; 36: 505–513.
18. Claycomb WC, Lanson NA, Stallworth BS. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 1998; 95: 2979–2984.
19. Dickstein K, Cohen-Solal A, Filippatos G. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Eur J Heart Fail 2008; 10: 933–989.
20. Wang M, Markel TA, Meldrum DR. Interleukin-18 in the heart. Shock 2008; 30: 3–10.
21. Chandrasekar B, Mummidi S, Claycomb WC. Interleukin-18 is a prohypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J Biol Chem 2005; 280: 4553–4567.
22. Morel JC, Park CC, Woods JM. A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatyldinositol(PI)-3-kinase-dependent signal transduction pathways. J Biol Chem 2001; 276: 37069–37075.
23. Matsui T, Nagoshi T, Rosenzweig A. Akt and PI3-kinase signalling in cardiomyocyte hypertrophy and survival. Cell Cycle 2003; 2: 220–223.
24. Brewer A, Pizzey J. GATA factors in vertebrate heart development and disease. Expert Rev Mol Med 2006 15; 8: 1–20.
25. Reddy VS, Harskamp RE, van Ginkel MW. Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-Akt-dependent NF-kappaB activation. J Cell Physiol 2008; 215: 697–707.
26. Yu Q, Vasquez R, Vali Khoejeini E. IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am J Physiol Heart Circ Physiol 2009; 297: 76–85.
27. Kapoun AM, Liang F, O’Young G. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, inflammation, myofibroblast conversion, and inflammation. Circ Res 2004; 94: 453–461.
28. Yamaoka-Tojo M, Tojo T, Inomata T. Circulating levels of Interleukin-18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exagerates the pathophysiology of advanced heart failure. J Cardiac Fail 2002; 8: 21–27.
29. Suchanek H, Mysliwska J, Siebert J. High serum interleukin-18 concentration in patients with coronary heart disease and type 2 diabetes mellitus. Eur Cytokine Netw 2005; 16: 177–185.
30. Seta Y, Kanda T, Tanaka T. Interleukin-18 in patients with congestive heart failure: induction of atrial natriuretic peptide gene expression. Res Comun Mol Pathol Pharmacol 2000; 108: 87–95.
31. Kazanegra R, Cheng V, Garcia A. A rapid test for B-type natriuretic peptide correlates with falling wedge pressure in patients treated for decompensated heart failure: a pilot study. J Card Fail 2001; 7: 21–29.
32. La Pointe MC. Molecular regulation of the brain natriuretic gene. Peptides 2005; 26: 944–956.
33. Di Somma S, Magrini L, Tabacco F. Brain natriuretic peptide and N-terminal pro-B-type natriuretic peptide show a different profile in response to acute decompensated heart failure treatment. Congest Heart Fail 2008: 14: 245–250.
34. Yamaoka-Toyo M, Tojo T, Masuda T. C-reactive protein-induced production of IL-18 in human endothelial cells: a mechanism of orchestrating cytokine cascade in acute coronary syndrome. Heart Vessels 2003; 18: 183–187.
35. Mallat Z, Corbaz A, Scoazec A. Expression of IL18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598–1603.
36. Pomerantz B, Reznikov LL, Harken AH. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1β. Proc Natl Acad Sci USA 2001; 98: 2871–2876.
37. Woldbaek PR, Tonnesen T, Henriksen T. Increased cardiac -18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Card Res 2003; 59: 122–131.
38. Kragelund G, Gronning B, Kober L. NT-terminal pro-B-type natriuretic peptide and long term mortality in stable coronary heart disease N Eng J Med 2005; 352: 666–675.
39. Esposito K, Nappo F, Marfella R. Cyokine milieu tends to inflammation in type 2 diabetes. Diabetes Care 2003; 26: 1647.
40. Leick L, Lindegaard B, Stensvold D. Adipose tissue interleukin-18 mRNA and plasma interleukin-18: effects of obesity and exercise. Obesity 2007; 15: 356–363.
41. Porazko T, Kúzniar J, Kusztal M. IL-18 is involved in vascular injury in end-stage renal disease patients. Nefrol Dial Transplant 2009; 24: 589–596.
42. Parikh CR, Devarajan P. New biomarkers of acute kidney injury. Crit Care Med 2008; 36: 159–165.
43. Porazko T, Kuzniar J, Kusztal M, Kuzniar TJ, Weyde W, Kuriata-Kordek M, Klinger M. IL-18 is involved in vascular injury in end-stage renal disease patients. Nephrol Dial Transplant 2009; 24: 298–96.
44. Parikh CR, Devarajan P. New biomarkers of acute kidney injury. Crit Care Med 2008; 36: 159–65.
45. Bombardieri M, McInnes IB, Pitzalis C. Interleukin-18 as a potential therapeutic target in chronic autoimmune/ inflammatory conditions. Expert Opin Biol Ther 2007; 7: 31–40.
46. Pina IL, O’Connor C. BNP-guided therapy for heart failure. JAMA 2009; 30: 432–34.